Leonardo Fabbri Selected Research

Pneumonia (Pneumonitis)

1/2018

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leonardo Fabbri Research Topics

Disease

6	Chronic Obstructive Pulmonary Disease (COPD) 12/2018 - 04/2004
4	Asthma (Bronchial Asthma) 01/2022 - 06/2012
1	Pneumonia (Pneumonitis) 01/2018
1	Reinfection 08/2015
1	Emphysema 01/2014
1	Bronchiolitis 01/2014

Drug/Important Bio-Agent (IBA)

6	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 06/2012
3	Muscarinic AntagonistsIBA 01/2022 - 04/2011
3	Beclomethasone (Beclometasone)FDA Link 01/2018 - 06/2012
3	Formoterol Fumarate (Oxis)FDA Link 01/2018 - 06/2012
2	Bronchodilator Agents (Bronchodilators)IBA 01/2022 - 01/2018
2	GoldIBA 08/2015 - 04/2004
2	Fluticasone-Salmeterol Drug Combination (Advair)FDA Link 12/2012 - 06/2012
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2022
1	dupilumabIBA 01/2019
1	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 01/2018
1	indacaterolIBA 01/2018
1	Broncho-VaxomIBA 08/2015
1	Bacterial LysatesIBA 08/2015
1	Carbon MonoxideIBA 01/2014
1	fluticasone furoate FDA Link 04/2013
1	vilanterolIBA 04/2013
1	Fluticasone (Cutivate)FDA LinkGeneric 12/2012
1	Budesonide (Pulmicort)FDA LinkGeneric 12/2012
1	aclidinium bromideIBA 04/2011

Therapy/Procedure

6	Therapeutics 01/2022 - 06/2012
2	Nebulizers and Vaporizers (Inhaler) 01/2022 - 01/2018